tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Eye Infections, Fungal D015821 2 associated lipids
Deglutition Disorders D003680 2 associated lipids
Discitis D015299 2 associated lipids
Fox-Fordyce Disease D005588 2 associated lipids
Collagen Diseases D003095 2 associated lipids
Multiple Pulmonary Nodules D055613 2 associated lipids
Cholecystolithiasis D041761 2 associated lipids
Brachial Plexus Neuritis D020968 2 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Pruritus Ani D011538 2 associated lipids
Vestibular Diseases D015837 2 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Arthritis, Reactive D016918 3 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Intestinal Atresia D007409 3 associated lipids
Foot Dermatoses D005533 3 associated lipids
Hyperkalemia D006947 3 associated lipids
Epstein-Barr Virus Infections D020031 3 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Immune System Diseases D007154 3 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Hematologic Diseases D006402 3 associated lipids
Anus Diseases D001004 3 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Castleman Disease D005871 3 associated lipids
Acneiform Eruptions D017486 3 associated lipids
Scleritis D015423 3 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Digestive System Diseases D004066 3 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Ileus D045823 3 associated lipids
Anemia, Refractory D000753 3 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Wounds, Stab D014951 3 associated lipids
Uveitis, Intermediate D015867 3 associated lipids
Legionellosis D007876 3 associated lipids
Pityriasis D010915 3 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Glomerulonephritis, Membranoproliferative D015432 3 associated lipids
Keratosis, Actinic D055623 3 associated lipids
Failed Back Surgery Syndrome D055111 3 associated lipids
Perceptual Disorders D010468 3 associated lipids
Fetal Hypoxia D005311 3 associated lipids
Lichen Planus D008010 3 associated lipids
Toxocariasis D014120 3 associated lipids
Pyoderma Gangrenosum D017511 3 associated lipids
Impetigo D007169 3 associated lipids
Polyneuropathies D011115 3 associated lipids
Trichomonas Infections D014245 3 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Paronychia D010304 3 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Meningococcal Infections D008589 3 associated lipids
Nervous System Autoimmune Disease, Experimental D020721 3 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Gingival Hyperplasia D005885 3 associated lipids
Facial Neoplasms D005153 3 associated lipids
Gingivitis D005891 3 associated lipids
Hemophilia B D002836 3 associated lipids
Pouchitis D019449 3 associated lipids
Cryptococcosis D003453 3 associated lipids
Pemphigus D010392 3 associated lipids
Dysgammaglobulinemia D004406 3 associated lipids
Pterygium D011625 3 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Hyperparathyroidism, Secondary D006962 4 associated lipids
Bone Diseases D001847 4 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Eczema D004485 4 associated lipids
Foot Ulcer D016523 4 associated lipids
Red-Cell Aplasia, Pure D012010 4 associated lipids
Neuritis D009443 4 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Dermatitis, Perioral D019557 4 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Headache D006261 4 associated lipids
Pain, Intractable D010148 4 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Balanitis D001446 4 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Amenorrhea D000568 4 associated lipids
Blepharitis D001762 4 associated lipids
Diabetes Complications D048909 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Glomerulosclerosis, Focal Segmental D005923 4 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Hallucinations D006212 4 associated lipids
Meningoencephalitis D008590 4 associated lipids
Herpesviridae Infections D006566 4 associated lipids
Prurigo D011536 4 associated lipids
Viremia D014766 4 associated lipids
Gastroenteritis D005759 4 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Meiser BM et al. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. 1991 Lancet pmid:1719321
Watanabe K et al. Donor bone marrow cell facilitates induction of tolerance to kidney allografts in dogs treated with fractionated lymphoid irradiation and FK 506. 1991 Transplant. Proc. pmid:1703706
Jorgensen WL Rusting of the lock and key model for protein-ligand binding. 1991 Science pmid:1719636
Kobayashi N et al. Significance of pancreatic allograft rejection in swine abdominal organ cluster transplantation. 1991 Transplant. Proc. pmid:1703707
Keenan RJ et al. Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. 1991 Transplantation pmid:1719668
Strasser S et al. The effect of FK 506 on canine pancreatic islet cell function in beagle dogs. 1991 Transplant. Proc. pmid:1703709
Cryan J et al. FKBP, the binding protein for the immunosuppressive drug, FK-506, is not an inhibitor of protein kinase C activity. 1991 Biochem. Biophys. Res. Commun. pmid:1719972
Ryu S and Yasunami Y Prevention of immune rejection in rat islet allografts by continuous SC administration of FK 506 using a mini-osmotic pump. 1991 Transplant. Proc. pmid:1703710
Karlsson H et al. The immunosuppressive agent FK506 inhibits in vitro expression of membrane-bound and soluble interleukin-2 receptors on resting but not on activated human lymphocytes. 1991 Immunol. Lett. pmid:1720417
Alejandro R et al. Combined liver-islet allotransplantation in man under FK 506. 1991 Transplant. Proc. pmid:1703712
FK-506 shows similar graft survival rate to cyclosporine but fewer side effects: Pitt transplant team. 1991 Nephrol News Issues pmid:1720511
Ito T et al. The mechanism of tolerance induced by a perioperative injection of bone marrow cells and a brief course of FK 506. 1991 Transplant. Proc. pmid:1703716
The discovery of FK-506 and U.S. development. 1991 Nephrol News Issues pmid:1720512
Zheng B et al. Effects of the new and highly active immunosuppressant, rapamycin, on lymphoid tissues and cells in vivo. 1991 Transplant. Proc. pmid:1703717
Mieles L et al. Interaction between FK506 and clotrimazole in a liver transplant recipient. 1991 Transplantation pmid:1721250
Yabuuchi H et al. Prominent prolongation of islet xenograft survival in combination therapy with FK 506 and 15-deoxyspergualin. 1991 Transplant. Proc. pmid:1703718
Sumpio BE and Phan S Nephrotoxic potential of FK 506. 1991 Transplant. Proc. pmid:1721278
Pichard L et al. Effect of FK 506 on human hepatic cytochromes P-450: interaction with CyA. 1991 Transplant. Proc. pmid:1721279
Christians U et al. Interactions of FK 506 and cyclosporine metabolism. 1991 Transplant. Proc. pmid:1721280
Wu YM et al. Interaction between FK 506 and cyclosporine in dogs. 1991 Transplant. Proc. pmid:1721281
Habucky K et al. The pharmacodynamics of pentobarbital following FK 506 therapy. 1991 Transplant. Proc. pmid:1721282
Farghali H et al. Effect of FK 506 chronic administration on bromosulphthalein hepatic excretion in rats. 1991 Transplant. Proc. pmid:1721283
Farghali H et al. A biochemical and 31P-NMR investigation of the effect of FK 506 and cyclosporine pretreatment on immobilized hepatocytes perifused with ethanol. 1991 Transplant. Proc. pmid:1721284
Farghali H et al. FK 506 modulates D-galactosamine-induced hepatitis in rats. 1991 Transplant. Proc. pmid:1721285
de Paulis A et al. Antiinflammatory effect of FK 506 on human basophils. 1991 Transplant. Proc. pmid:1721309
Su MS and Semerjian A Activation of transcription factor NF kappa B in Jurkat cells is inhibited selectively by FK 506 in a signal-dependent manner. 1991 Transplant. Proc. pmid:1721310
Andersson J et al. The effects of FK 506 on cytokine production are dependent on the mode of cell activation. 1991 Transplant. Proc. pmid:1721311
Wang SC et al. FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line. 1991 Transplant. Proc. pmid:1721312
Woo J et al. Kinetics of early T-cell repopulation in the mouse following syngeneic bone marrow transplantation: FK 506 causes a maturational defect of CD4+ CD8- T cells. 1991 Transplant. Proc. pmid:1721313
McCarthy SA et al. Effects of FK 506 and cyclosporine on T-cell tolerance: inhibition of a "protective" mechanism that regulates activation-induced apoptosis in developing thymocytes. 1991 Transplant. Proc. pmid:1721314
Zeevi A et al. Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin. 1991 Transplant. Proc. pmid:1721315
Matsuura T et al. Beneficial immunosuppressive effect of combined use of FK 506 and cyclosporine assessed by proliferative responses of cloned human T cells. 1991 Transplant. Proc. pmid:1721316
Jiang H et al. Combined immunosuppressive effect of FK 506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro. 1991 Transplant. Proc. pmid:1721317
Reding R et al. Compassionate use of FK 506 in pediatric liver transplantation: a pilot study. 1991 Transplant. Proc. pmid:1721341
Uemoto S et al. Experience with FK 506 in living related donor liver transplantation. 1991 Transplant. Proc. pmid:1721342
Tzakis AG et al. FK 506 versus cyclosporine in pediatric liver transplantation. 1991 Transplant. Proc. pmid:1721343
Mieles LA et al. Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. 1991 Transplant. Proc. pmid:1721344
Nakazato P et al. Early experience with FK 506 induction immunosuppression--suggestion for using oral FK 506. 1991 Transplant. Proc. pmid:1721345
Nakamura K et al. The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. 1991 Transplant. Proc. pmid:1721346
Jain AB et al. Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. 1991 Transplant. Proc. pmid:1721347
Takaya S et al. Retransplantation of liver: a comparison of FK 506- and cyclosporine-treated patients. 1991 Transplant. Proc. pmid:1721348
Clinicopathological evaluation of kidney transplants in patients given a fixed dose of FK 506. Japanese FK 506 Study Group. 1991 Transplant. Proc. pmid:1721374
Christians U et al. Measurement of FK 506 by HPLC and isolation and characterization of its metabolites. 1991 Transplant. Proc. pmid:1703358
Morris SM et al. Disruption of renal function and gene expression by FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721375
Lagodziński Z et al. Effect of FK 506 on B-cell responses. 1991 Transplant. Proc. pmid:1703359
Lieberman KV et al. FK 506 is a direct glomeruloconstrictor, as determined by electrical resistance pulse sizing (ERPS). 1991 Transplant. Proc. pmid:1721376
Demetris AJ et al. Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine. 1991 Transplant. Proc. pmid:1703360
Ueda D et al. Influence of FK 506 on renal blood flow. 1991 Transplant. Proc. pmid:1721377
Thomson AW et al. The influence of FK 506 on the thymus: implications of drug-induced injury to thymic epithelial cells. 1991 Transplant. Proc. pmid:1703361
Perico N et al. FK 506 does not affect the glomerular filtration rate and renal plasma flow in the rat. 1991 Transplant. Proc. pmid:1721378
Mieles L et al. Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients. 1991 Transplant. Proc. pmid:1703362
Wagner K et al. Effect of FK 506 on excretion of urinary enzymes in rats. 1991 Transplant. Proc. pmid:1721379
Warty V et al. Distribution of FK 506 in plasma lipoproteins in transplant patients. 1991 Transplant. Proc. pmid:1703363
Prasad SJ et al. In vitro effects of cyclosporine and FK 506 on the renal cortex. 1991 Transplant. Proc. pmid:1721380
Kusne S et al. Early infections in kidney transplant recipients under FK 506. 1991 Transplant. Proc. pmid:1703364
Yamada K et al. Short-term FK 506-induced morphological changes in rat kidneys. 1991 Transplant. Proc. pmid:1721381
Abu-Elmagd KM et al. Acute hemolytic anemia in liver and bone marrow transplant patients under FK 506 therapy. 1991 Transplant. Proc. pmid:1721404
Adams CK and Famili P A study of the effects of the drug FK 506 on gingival tissues. 1991 Transplant. Proc. pmid:1721405
Pirsch JD et al. Pulmonary infiltrates and eosinophilia in an FK 506 liver transplant recipient. 1991 Transplant. Proc. pmid:1721406
Shinozuka H et al. Effect of FK 506 on experimental liver carcinogenesis. 1991 Transplant. Proc. pmid:1721407
Pelekanou V et al. FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function. 1991 Transplant. Proc. pmid:1721408
Tai J et al. In vivo and in vitro effect of FK 506 on rat Leydig cell function. 1991 Transplant. Proc. pmid:1721409
Ricordi C et al. Human islet allotransplantation under FK 506. 1991 Transplant. Proc. pmid:1721410
Tze WJ et al. Long-term survival of islet allografts in diabetic rats treated with FK 506. 1991 Transplant. Proc. pmid:1721411
Ito T et al. Bone marrow cell- and FK 506-induced donor-specific unresponsiveness in rat heart allografts. 1991 Transplant. Proc. pmid:1721437
DeValeria PA et al. FK 506 fails to reverse moderate cardiac allograft rejection in a canine heterotopic model. 1991 Transplant. Proc. pmid:1721438
Jiang H et al. Prolonged cardiac allograft survival in sensitized rats by low-dose FK 506 in combination with splenectomy. 1991 Transplant. Proc. pmid:1721439
Sakr MF et al. FK 506 ameliorates the hepatic injury associated with ischemia and reperfusion in rats. 1991 Hepatology pmid:1709412
Sato K et al. Comparative study of FK 506, cyclosporine, and triple regimen immunosuppression with FK 506, cyclosporine, and mizoribine. 1991 Transplant. Proc. pmid:1721440
Hohlfeld R [Current therapy of multiple sclerosis: value of cyclosporin A and FK 506]. 1991 Nervenarzt pmid:1709725
Katayama Y et al. Immunosuppressive effects of FK 506 in rat lung transplantation. 1991 Transplant. Proc. pmid:1721441
Kay JE et al. Inhibition of T and B lymphocyte proliferation by rapamycin. 1991 Immunology pmid:1709916
Yokomise H et al. Immunosuppressive effects of FK 506 in canine lung transplantation. 1991 Transplant. Proc. pmid:1721442
Ringe D Immunosuppression. Binding by design. 1991 Nature pmid:1710317
Hasegawa S et al. FK 506 and cyclosporine: effects and side effects in canine lung transplantation. 1991 Transplant. Proc. pmid:1721443
Tropschug M and Hofmann R FK506 and protein kinase C. 1991 Nature pmid:1710319
Wada H et al. Dose response to FK 506 in canine lung transplantation. 1991 Transplant. Proc. pmid:1721444
Albers MW et al. Relationship of FKBP to PKCI-2. 1991 Nature pmid:1710782
Stevens C et al. The effects of immunosuppressive agents on in vitro production of human immunoglobulins. 1991 Transplantation pmid:1710843
Metcalfe S and Milner J Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A. 1991 Transplantation pmid:1710844
Chang JY et al. FK506 and rapamycin: novel pharmacological probes of the immune response. 1991 Trends Pharmacol. Sci. pmid:1710854
Nicoletti F et al. FK-506 prevents diabetes in diabetes-prone BB/Wor rats. 1991 Int. J. Immunopharmacol. pmid:1722192
Starzl TE et al. [Clinical experience with FK 506]. 1991 Presse Med pmid:1722311
Granelli-Piperno A and McHugh P Characterization of a protein that regulates the DNA-binding activity of NF-AT, the nuclear factor of activated T cells. 1991 Proc. Natl. Acad. Sci. U.S.A. pmid:1722332
Simmons RL and Wang SC New horizons in immunosuppression. 1991 Transplant. Proc. pmid:1714645
Nelson PA et al. cDNA encoding murine FK506-binding protein (FKBP): nucleotide and deduced amino acid sequence. 1991 Gene pmid:1722474
Calne RY Immunosuppression for organ grafting. 1991 Transplant. Proc. pmid:1714646
Chen MF et al. The influence of FK-506 on the thymus and spleen in normal C3H/He mice: flow cytometric analysis of lymphocyte subpopulations. 1991 Immunol. Lett. pmid:1722778
Starzl TE et al. Notes on FK 506. 1991 Transplant. Proc. pmid:1714647
Sakai K et al. The effect of a new immunosuppressive agent, FK-506, on xenogeneic neural transplantation in rodents. 1991 Brain Res. pmid:1723023
Haba T et al. Pathological and immunohistochemical examination in the rat treated with FK 506. 1991 Transplant. Proc. pmid:1714649
Forrest MJ et al. FK-506 and cyclosporin A: selective inhibition of calcium ionophore-induced polymorphonuclear leukocyte degranulation. 1991 Biochem. Pharmacol. pmid:1716098
Weaver JL et al. Comparison of the in vitro and biophysical effects of cyclosporine A, FK-506, and mycophenolic acid on human peripheral blood lymphocytes. 1991 Immunopharmacol Immunotoxicol pmid:1723084
Lautenschlager I et al. Efficiency of FK 506 and CyA to prevent acute cellular rejection of pig liver allografts. 1991 Transplant. Proc. pmid:1714650
DiLella AG and Craig RJ Exon organization of the human FKBP-12 gene: correlation with structural and functional protein domains. 1991 Biochemistry pmid:1716149
Burres NS et al. Dunaimycins, a new complex of spiroketal 24-membered macrolides with immunosuppressive activity. III. Immunosuppressive activities of dunaimycins. 1991 J. Antibiot. pmid:1723403
Epand RF and Epand RM The new potent immunosuppressant FK-506 reverses multidrug resistance in Chinese hamster ovary cells. 1991 Anticancer Drug Des. pmid:1714737
McKeon F When worlds collide: immunosuppressants meet protein phosphatases. 1991 Cell pmid:1716181
Christians U et al. Isolation of an immunosuppressive metabolite of FK506 generated by human microsome preparations. 1991 Clin. Biochem. pmid:1714802
Turka LA and Thompson CB Structure-function relationship of immunosuppressive drugs: a cautionary tale. 1991 Hepatology pmid:1714876